Related Experiment Video

Updated: Sep 12, 2025

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.4K

Sodium-glucose cotransporter 2 inhibitors and atherosclerosis

Alexandr Ceasovschih1,2, Anastasia Balta1, Essam Shams Aldeen1

  • 1Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, Iasi, Romania.

American Journal of Preventive Cardiology
|August 8, 2025
PubMed

Insights

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) offer significant cardiovascular benefits beyond glucose control. These agents demonstrate atheroprotective effects and improve vascular function, making them valuable in managing atherosclerotic cardiovascular disease.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel therapeutic class with established cardiovascular benefits.
  • Their impact on atherosclerosis and related vascular conditions requires comprehensive synthesis.

Purpose of the Study:

  • To review clinical and preclinical evidence on SGLT2i effects on atherosclerosis, arterial stiffness, and associated cardiovascular diseases.
  • To elucidate the mechanisms underlying the atheroprotective advantages of SGLT2i.

Main Methods:

  • Systematic review of clinical and preclinical studies.
  • Synthesis of evidence on SGLT2i impact on dyslipidemia, coronary artery disease, peripheral artery disease, and stroke.

Main Results:

  • SGLT2i demonstrate atheroprotective effects through multiple mechanisms, including anti-inflammatory, antioxidant, and improved vascular function.
  • Benefits extend to glycemic control, weight reduction, blood pressure management, and antifibrotic actions.
  • SGLT2i exhibit a favorable safety profile and compatibility with combination therapies.

Conclusions:

  • SGLT2i offer broad cardiovascular benefits, significantly impacting atherosclerotic cardiovascular disease management.
  • These agents are advancing the paradigm of cardiovascular disease care with a favorable safety profile.
  • Accumulating evidence supports SGLT2i as key agents in combating atherosclerosis.
Keywords:
Arterial stiffnessAtherosclerosisCardiovascular diseasesCerebrovascular diseaseDyslipidemiaSGLT2 inhibitors

More Related Videos

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

9.8K
Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

20.2K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
298
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
262
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
260
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.6K
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
332